Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alembic PharmaceuticalsNSE:APLLTD +0.01%87 EV-to-EBIT is 21.33 as of Aug. 15, 2026, which is 8% above its 10-year median of 19.84. GuruFocus rates NSE:APLLTD with a GF Score™ of 87/100 and a GF Value™ of ₹1,099.66 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 682 Drug Manufacturers companies, Alembic Pharmaceuticals ranks worse than 59.68% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Alembic Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was ₹161,722 Mil.
Alembic Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,234 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alembic Pharmaceuticals EV-to-EBIT Related Terms
Alembic Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alembic Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alembic Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alembic Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Alembic Pharmaceuticals's EV-to-EBIT falls into.
Alembic Pharmaceuticals's current Enterprise Value is ₹175,661 Mil.
Alembic Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,234 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alembic Pharmaceuticals (NSE:APLLTD) has a EV-to-EBIT of 21.33 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alembic Pharmaceuticals and its competitors. This is near median its historical median of 19.84. Over the past decade, Alembic Pharmaceuticals' EV-to-EBIT has ranged from 11.20 to 39.35. According to the industry distribution chart, Alembic Pharmaceuticals ranks #407 out of 682 companies in the Drug Manufacturers industry, placing it in the top 59.7%.
Is Alembic Pharmaceuticals' EV-to-EBIT too high?
Alembic Pharmaceuticals' current EV-to-EBIT of 21.33 is near median its 10-year median of 19.84. Over the past 10 years, this metric has ranged from a low of 11.20 to a high of 39.35. The Drug Manufacturers industry median EV-to-EBIT is 15.86. Alembic Pharmaceuticals' value of 21.33 is 34.5% above this industry median. Based on the distribution chart, Alembic Pharmaceuticals ranks #407 out of 682 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Alembic Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alembic Pharmaceuticals' EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alembic Pharmaceuticals ranks #407 out of 682 companies for EV-to-EBIT. This places Alembic Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 15.86. Alembic Pharmaceuticals' value of 21.33 is 34.5% above this benchmark. Historically, Alembic Pharmaceuticals' own EV-to-EBIT has ranged from 11.20 to 39.35 over the past decade. While the company's 10-year median is 19.84 vs. the industry median of 15.86, Alembic Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.86, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alembic Pharmaceuticals's current EV-to-EBIT of 21.33 is 34.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Alembic Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alembic Pharmaceuticals's current EV-to-EBIT is 21.33, which is near median its own 10-year median of 19.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alembic Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alembic Pharmaceuticals (NSE:APLLTD) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,099.66, compared to a current price of ₹831.25 — trading 24.4% below its estimated fair value. The current EV-to-EBIT is 21.33, which is near median its 10-year median of 19.84 and 34.5% above the Drug Manufacturers industry median of 15.86. Alembic Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Alembic Pharmaceuticals (NSE:APLLTD), the current EV-to-EBIT is 21.33 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alembic Pharmaceuticals (NSE:APLLTD) Overvalued in 2026?
Based on GuruFocus' analysis, Alembic Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹831.25 is trading 24.4% below its estimated GF Value™ of ₹1,099.66.
GuruFocus considers Alembic Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:APLLTD:
EV-to-EBIT: 21.33 (near median its 10-year median of 19.84)
GF Value™: ₹1,099.66 vs. price of ₹831.25 (24.4% below fair value)
Industry Position: 34.5% above the Drug Manufacturers median (#407 of 682)
No single metric tells the full story. See the NSE:APLLTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alembic Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company focuses on manufacturing and marketing generic pharmaceutical products across the globe. Alembic also operates a branded formulation business that covers a range of therapeutic areas such as dermatology, oncology, ophthalmology, and injectable formulations. The company considers merger and acquisition investment as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities.
87GF Score
Get the complete analysis for NSE:APLLTD
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:APLLTD has been successfully added to your 
